Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq

NEXT STORY
Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences
PREV STORY
Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Innovation Pharmaceuticals Signs Drug Product Manufacturing Contract with CoreRx to Formulate and Package Brilacidin for Oral Mucositis in Sachet Form

BEVERLY, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a ...

author_avatar
NASDAQ Market News

Allarity Therapeutics will trade under new short name ALLR starting on 12 October 2020

author_avatar
NASDAQ Market News

Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections

– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial ...

author_avatar
NASDAQ Market News